ICOS CORP 4
4 · ICOS CORP · Filed Jan 30, 2007
Insider Transaction Report
Form 4
ICOS CORPICOS
Chang Shing
Senior VP, Drug Discovery
Transactions
- Disposition to Issuer
Stock Option (right to buy)
2007-01-29$7.09/sh−49,500$350,955→ 0 totalExercise: $26.91From: 2006-10-09Exp: 2016-10-08→ Common Stock (49,500 underlying) - Disposition to Issuer
Common Stock
2007-01-29$34.00/sh−16,500$561,000→ 0 total
Footnotes (3)
- [F1]Represents shares of restricted stock disposed of pursuant to the Merger Agreement under which Eli Lilly and Company ("Eli Lilly") acquired the issuer ("Merger") and which provides for the cancellation of shares of common stock of the Issuer in exchange $34.00 per share (the "Merger Consideration).
- [F2]The options vested monthly in 1/48th increments over four years (48 months) commencing on the grant date indicated.
- [F3]All options were cancelled pursuant to the Merger Agreement in exchange for cash consideration equal to the Merger Consideration less the exercise price per share.